Genmab A (GMAB) Other Operating Expenses (2019 - 2026)

Genmab A has reported Other Operating Expenses for 5 years, with the latest figure at -$65.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 54.76% year-over-year to -$65.0 million; the trailing twelve-month figure through Mar 2026 stood at -$180.0 million (down 63.64% YoY), and the FY2025 full-year result was $423.0 million, up 84.72% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$65.0 million, down from -$58.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was -$27.0 million in Q1 2024, with the low at -$65.0 million in Q1 2026.
• Historically, Other Operating Expenses has averaged -$45.3 million across 3 years, with a median of -$42.0 million in 2025.
• The largest YoY upside for Other Operating Expenses was 45.0% in 2025 against a maximum downside of 103.57% in 2025.
• Genmab A's Other Operating Expenses stood at -$40.0 million in 2024, then slumped by 45.0% to -$58.0 million in 2025, then dropped by 12.07% to -$65.0 million in 2026.
• The last three Other Operating Expenses figures came in at -$65.0 million (Q1 2026), -$58.0 million (Q3 2025), and -$57.0 million (Q2 2025), per Business Quant data.